skip to Main Content

A Phase 3 Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK)

The primary objective of this study is to evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events. Secondary objectives are:
1) To evaluate the anti-pneumococcal polysaccharide serotype-specific Immunoglobulin Geometric Mean Concentrations at 30 days following dose 3, prior to dose 4, and at 30 days following dose 4 for each vaccination group; and
2) To evaluate the anti-PnPs serotype-specific IgG response rates.

Investigator: Klein, Nicola

Funder: Merck & Company, Inc.

Explore all studies and publications

Back To Top